FOSTER CITY: Gilead Sciences Inc. announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company’s Board of Directors. Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology at the University of California San Francisco. He is…
SACRAMENTO: Gilead Sciences Inc. and Immunomedics have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88/share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020….
PRINCETON: Dr. Reddy’s Laboratories has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this drug….